D. Ross Camidge, MD, PhD, comments on the subgroup analysis of the PROFILE 1007 trial, which looked at crizotinib versus either pemetrexed or docetaxel in NSCLC.
D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, comments on the subgroup analysis of the PROFILE 1007 trial, which looked at crizotinib versus either pemetrexed or docetaxel in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
The control arm of this study (docetaxel or pemetrexed) was designed to differentiate between the two chemotherapies in this space. Though the two agents were originally thought to be nearly identical, pemetrexed stood out and performed better than docetaxel.
Patients treated with pemetrexed saw a nearly double progression-free survival rate compared to those treated with docetaxel. Pemetrexed stood out further as patients saw nearly a 30% response rate, which is unheard of for a chemotherapy in the second line, Camidge says.
Camidge says that the superiority of pemetrexed is still under investigation.
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More